247 related articles for article (PubMed ID: 24558007)
1. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.
Hsu J; Rappaport J; Muro S
Pharm Res; 2014 Jul; 31(7):1855-66. PubMed ID: 24558007
[TBL] [Abstract][Full Text] [Related]
2. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
Bhowmick T; Berk E; Cui X; Muzykantov VR; Muro S
J Control Release; 2012 Feb; 157(3):485-92. PubMed ID: 21951807
[TBL] [Abstract][Full Text] [Related]
3. A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.
Garnacho C; Serrano D; Muro S
J Pharmacol Exp Ther; 2012 Mar; 340(3):638-47. PubMed ID: 22160267
[TBL] [Abstract][Full Text] [Related]
4. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
Papademetriou I; Tsinas Z; Hsu J; Muro S
J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
[TBL] [Abstract][Full Text] [Related]
5. Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrier.
Loeck M; Placci M; Muro S
Drug Deliv Transl Res; 2023 Dec; 13(12):3077-3093. PubMed ID: 37341882
[TBL] [Abstract][Full Text] [Related]
6. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
7. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.
Kim J; Sinha S; Solomon M; Perez-Herrero E; Hsu J; Tsinas Z; Muro S
Biomaterials; 2017 Dec; 147():14-25. PubMed ID: 28923682
[TBL] [Abstract][Full Text] [Related]
8. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
Calderon AJ; Bhowmick T; Leferovich J; Burman B; Pichette B; Muzykantov V; Eckmann DM; Muro S
J Control Release; 2011 Feb; 150(1):37-44. PubMed ID: 21047540
[TBL] [Abstract][Full Text] [Related]
9. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
Muro S; Dziubla T; Qiu W; Leferovich J; Cui X; Berk E; Muzykantov VR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1161-9. PubMed ID: 16505161
[TBL] [Abstract][Full Text] [Related]
10. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
11. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.
Hsu J; Hoenicka J; Muro S
Pharm Res; 2015 Apr; 32(4):1264-78. PubMed ID: 25319100
[TBL] [Abstract][Full Text] [Related]
12. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
13. Distinct subcellular trafficking resulting from monomeric vs multimeric targeting to endothelial ICAM-1: implications for drug delivery.
Ghaffarian R; Muro S
Mol Pharm; 2014 Dec; 11(12):4350-62. PubMed ID: 25301142
[TBL] [Abstract][Full Text] [Related]
14. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
Muro S; Garnacho C; Champion JA; Leferovich J; Gajewski C; Schuchman EH; Mitragotri S; Muzykantov VR
Mol Ther; 2008 Aug; 16(8):1450-8. PubMed ID: 18560419
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
Muro S; Schuchman EH; Muzykantov VR
Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
[TBL] [Abstract][Full Text] [Related]
16. Intra- and trans-cellular delivery of enzymes by direct conjugation with non-multivalent anti-ICAM molecules.
Ghaffarian R; Roki N; Abouzeid A; Vreeland W; Muro S
J Control Release; 2016 Sep; 238():221-230. PubMed ID: 27473764
[TBL] [Abstract][Full Text] [Related]
17. Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.
Ghaffarian R; Bhowmick T; Muro S
J Control Release; 2012 Oct; 163(1):25-33. PubMed ID: 22698938
[TBL] [Abstract][Full Text] [Related]
18. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme.
Manthe RL; Loeck M; Bhowmick T; Solomon M; Muro S
J Control Release; 2020 Aug; 324():181-193. PubMed ID: 32389778
[TBL] [Abstract][Full Text] [Related]
19. β2 integrin-mediated crawling on endothelial ICAM-1 and ICAM-2 is a prerequisite for transcellular neutrophil diapedesis across the inflamed blood-brain barrier.
Gorina R; Lyck R; Vestweber D; Engelhardt B
J Immunol; 2014 Jan; 192(1):324-37. PubMed ID: 24259506
[TBL] [Abstract][Full Text] [Related]
20. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs.
Muro S; Gajewski C; Koval M; Muzykantov VR
Blood; 2005 Jan; 105(2):650-8. PubMed ID: 15367437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
